36 results on '"Shinozaki, K"'
Search Results
2. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer
3. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
4. Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial)
5. P-61 Impacts of salvage chemotherapy after nivolumab therapy (NIVO): A REVIVE substudy
6. Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathy
7. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)
8. P-196 Tumor response as a predictor of survival for RAS-WT left-sided mCRC administered first-line molecularly targeted drugs: An observational study by the Japanese Society for Cancer of the Colon and Rectum
9. P-165 First-line treatment with CET/PAN vs. BEV in elderly patients with RAS WT mCRC: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
10. IMPRESSIVE CASES OF ADVANCED GASTRIC CANCER SUCCESSFULLY MANAGED WITH TRASTUZUMAB CONTAINING CHEMOTHERAPY
11. 300MO Impact of dihydropyrimidine dehydrogenase (DPD) genotype on fluoropyrimidine-related toxicity in Asian population
12. Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2)
13. Efficacy and safety of a recombinant soluble human thrombomodulin (ART-123) in preventing oxaliplatin induced peripheral neuropathy (OIPN): Results of a placebo-controlled, randomized, double-blind phase II study
14. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases (CLM): A post hoc analysis of the WJOG4407G phase III study
15. Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B
16. REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis
17. Multicenter phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)
18. 757P - Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2)
19. Treatment of opioid-induced constipation with naldemedine in patients with cancer: onset of action in a randomized phase 3 trial
20. A nomogram for predicting overall survival (OS) in Japanese patients (pts) with advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens
21. 668P - Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B
22. 599P - Efficacy and safety of a recombinant soluble human thrombomodulin (ART-123) in preventing oxaliplatin induced peripheral neuropathy (OIPN): Results of a placebo-controlled, randomized, double-blind phase II study
23. 511P - Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases (CLM): A post hoc analysis of the WJOG4407G phase III study
24. PD-010 - REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis
25. 521P - Multicenter phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)
26. 1466P - Treatment of opioid-induced constipation with naldemedine in patients with cancer: onset of action in a randomized phase 3 trial
27. 579P - A nomogram for predicting overall survival (OS) in Japanese patients (pts) with advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens
28. A Randomized, Double-Blind, Placebo-Controlled PIII Study of Fentanyl Buccal Tablet (FBT) for Breakthrough Cancer Pain
29. Investigation and Prevention of Fosaprepitant-Induced Vascular Pain
30. Comparison Between Primary Tumor Resection and Primary Chemotherapy for Patients with Unresectable Colorectal Cancer
31. Randomized Phase III Study of Irinotecan (CPT-11) Versus Weekly Paclitaxel (WPTX) for Advanced Gastric Cancer (AGC) Refractory to Combination Chemotherapy (CT) of Fluoropyrimidine Plus Platinum (FP): WJOG4007 Trial
32. Two Autopsy Cases of Cancer of Unknown Primary which were Needed to be Distinguished from Adrenal Cancer
33. Prospective Validation of Patient Neurotoxicity Questionnaire (PNQ) for Assessment of Oxaliplatin Neurotoxicty: CSP-HOR 16
34. O1–056A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PIII STUDY OF FENTANYL BUCCAL TABLET (FBT) FOR BREAKTHROUGH CANCER PAIN.
35. O2–093COMPARISON BETWEEN PRIMARY TUMOR RESECTION AND PRIMARY CHEMOTHERAPY FOR PATIENTS WITH UNRESECTABLE COLORECTAL CANCER.
36. P3–106INVESTIGATION AND PREVENTION OF FOSAPREPITANT-INDUCED VASCULAR PAIN.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.